Background: Chronic renal insufficiency (CRI) is a common disease in cats. Angiotensin-converting enzyme inhibitors (ACEI) have beneficial effects in humans with CRI by reducing the loss of protein in the urine and increasing life expectancy. Hypothesis: The ACEI benazepril has beneficial effects on survival, clinical variables, or both as compared with placebo in cats with CRI. Animals: 61 cats with naturally occurring CRI. Methods: The cats were enrolled into a prospective, randomized, double-blind, placebo-controlled clinical trial. Cats received placebo or 0.5–1 mg/kg benazepril once daily for up to 6 months. Results: Urine protein/urine creatinine ratios were significantly (P < .05) lower with benazepril as compared with placebo at days 120 and 180. Three cats with placebo and 1 cat with benazepril were removed prematurely from the study because of deterioration of CRI or death. Cats were classified into 4 stages of CRI according to the International Renal Interest Society (IRIS) classification scheme. Incidence rates of cats with IRIS classification stage 2 or stage 3 that remained in stage 2 or 3 without progressing to stage 4 were higher with benazepril (93 ± 5%) as compared with placebo (73 ± 13%). Clinical Importance: These results suggest a potential for benazepril to delay the progression of disease, extend survival time, or both in cats with CRI.
No takes yet. Share an insight, caveat, or question.
Mizutani et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: